HopeStage
Back to overview

Depression studies

Topics
More filters

Depression

Depression involves persistent low mood or loss of interest, often with tiredness and changes in sleep or appetite.

7264studies shown
Showing 2,089-2,100 of 7,264
Device study icon
Active Not RecruitingNCT07102017

A Controlled study of Robotic Support for Enhanced Later Life (RoSELL)

Official study title

The Impact of Socially Supportive Robotic Intervention on Loneliness, Depression, Self-agency and Well-being in Long-term Care Residents: A Three-Arm Randomized Controlled Trial

This study is no longer accepting new participants.

In Shanghai
DepressionDevice studyAges 65+
Countries
China
Sponsor
Shanghai Jiao Tong University School of Medicine
Drug study icon
Active Not RecruitingNCT06775379

A Study of Azetukalner Versus Placebo in Major Depressive Disorder

What is this study about?

Researchers are comparing Azetukalner and placebo to find out how the approaches affect depression symptoms in people with depression.

This study is no longer accepting new participants.

Multiple locations, including Phoenix
DepressionMedication studyAges 18–74
Countries
United States
Sponsor
Xenon Pharmaceuticals Inc.
Drug study icon
Active Not RecruitingNCT07076407

A Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

What is this study about?

Researchers are comparing Azetukalner and placebo to find out how the approaches affect depression symptoms in people with depression.

This study is no longer accepting new participants.

Multiple locations, including Dothan
DepressionMedication studyAges 18–74
Countries
United States, Finland, Germany, + 4 others
Sponsor
Xenon Pharmaceuticals Inc.
Drug study icon
CompletedNCT01941043

CERC-301 for depression

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
Depression, SuicidalityMedication studyAges 18–70
Countries
United States
Sponsor
Avalo Therapeutics, Inc.
Drug study icon
CompletedNCT02476058

Safety study of JNJ-42847922 in depression

What is this study about?

Researchers compared JNJ-42847922, Diphenhydramine and placebo, tracking side effects to assess safety and tolerability in people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Aalst
DepressionMedication studyAges 18–64
Countries
Belgium, Germany, Netherlands
Sponsor
Janssen-Cilag International NV
Drug study icon
CompletedNCT00095758

Adjunctive Aripiprazole in people with Major Depressive Disorder

Official study title

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Beverly Hills
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00105196

Aripiprazole in people with Major Depressive Disorder

Official study title

A Study of Aripiprazole in Patients With Major Depressive Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT06254612

SP-624 for depression

What is this study about?

Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Phoenix
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Sirtsei Pharmaceuticals, Inc.
Drug study icon
CompletedNCT04479852

Safety and Efficacy of SP-624 for depression

What is this study about?

Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Phoenix
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Sirtsei Pharmaceuticals, Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.